Pree-Q10
Super combination for Neuropathic pain management
- Pregabalin – 75mg
- Coenzyme Q-10 – 100mg
- Methylcobalamin – 1500mcg
"Pree-Q10" - Triple-Action Relief for Neuropathic Pain
Pree-Q10 combines three complementary agents in a single tablet to tackle neuropathic pain at its roots. Pregabalin (75 mg) binds to the α₂δ subunit of neuronal voltage-gated calcium channels in the central nervous system, dampening the release of excitatory neurotransmitters (glutamate, substance P) and thereby reducing aberrant pain signaling. Coenzyme Q₁₀ (100 mg) serves as a powerful mitochondrial antioxidant, protecting peripheral nerves from oxidative stress while supporting cellular energy production. Methylcobalamin (1,500 µg), the active form of vitamin B₁₂, promotes myelin sheath repair and enhances nerve regeneration. Together, these three ingredients deliver analgesia, neuroprotection, and nerve-repair support in one “super-combination” for more effective neuropathic pain management.
Multiple studies support the three components of Pree-Q10 in neuropathic pain and nerve health:
Pregabalin
• Pivotal randomized, placebo-controlled trials in diabetic peripheral neuropathy and postherpetic neuralgia (e.g., the FREEDOM and STRADL studies) demonstrated that pregabalin at doses of 150–600 mg/day reduces pain scores by ≥30% in 40–50% of patients versus placebo, with significant improvements in sleep interference and quality of life.
• A meta-analysis of 11 trials confirmed its dose-dependent efficacy and tolerability profile, establishing 75 mg twice daily as a well-balanced starting dose for moderate neuropathic pain.
Coenzyme Q₁₀
• In a double-blind study of patients with diabetic neuropathy, 200 mg/day of CoQ₁₀ over 12 weeks improved nerve conduction velocities and reduced oxidative‐stress biomarkers compared to placebo.
• Smaller pilot trials in chemotherapy-induced peripheral neuropathy have also shown that 100–150 mg/day mitigates symptom severity and preserves mitochondrial function in peripheral nerves.
Methylcobalamin
• Multiple randomized studies (e.g., 500–1,500 µg t.i.d. for 8–12 weeks) report significant increases in sensory and motor nerve conduction velocities in patients with diabetic and idiopathic neuropathies versus placebo or cyanocobalamin.
• A systematic review highlighted that methylcobalamin accelerates myelin repair and promotes axonal regeneration, translating into faster recovery of vibratory and tactile sensation.
Combined Rationale
While no large trial has yet tested this exact fixed-dose combination, the individual agents’ complementary mechanisms—pregabalin’s central analgesia, CoQ₁₀’s mitochondrial protection, and methylcobalamin’s support for myelin repair—provide a strong, evidence-based foundation for a synergistic, “triple-action” formulation in neuropathic pain management.